Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
Article Details
- CitationCopy to clipboard
Pick A, Muller H, Wiese M
Novel lead for potent inhibitors of breast cancer resistance protein (BCRP).
Bioorg Med Chem Lett. 2010 Jan 1;20(1):180-3. doi: 10.1016/j.bmcl.2009.11.004. Epub 2009 Nov 10.
- PubMed ID
- 19932960 [ View in PubMed]
- Abstract
From our modulator library an interesting inhibitor of breast cancer resistance protein (BCRP) was identified. Due to its high inhibitory potency, this compound may serve as a promising novel lead for the design of new and potent modulators. This adds a new structural class to the few known highly active BCRP inhibitors.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Elacridar ATP-binding cassette sub-family G member 2 IC 50 (nM) 430 N/A N/A Details Elacridar ATP-binding cassette sub-family G member 2 IC 50 (nM) 400 N/A N/A Details Gefitinib ATP-binding cassette sub-family G member 2 IC 50 (nM) 1260 N/A N/A Details Gefitinib ATP-binding cassette sub-family G member 2 IC 50 (nM) 1100 N/A N/A Details Imatinib ATP-binding cassette sub-family G member 2 IC 50 (nM) 3380 N/A N/A Details Imatinib ATP-binding cassette sub-family G member 2 IC 50 (nM) 4070 N/A N/A Details